Alzamend Neuro Inc
NASDAQTotal Valuation
Alzamend Neuro Inc carries a market capitalization of 6.27M, placing it among publicly traded companies globally.
| Market Cap | 6.27M |
| Enterprise Value | N/A |
Share Statistics
Alzamend Neuro Inc currently has 4.83M shares outstanding.
| Shares Outstanding | 4.83M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 1.09 |
| P/TBV Ratio | 1.09 |
| P/FCF Ratio | -0.74 |
| P/OCF Ratio | -0.74 |
Financial Position
Alzamend Neuro Inc maintains a current ratio of 3.01, meaning it holds 3.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 3.01 |
| Quick Ratio | 2.77 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -1,462.51 |
Financial Efficiency
| Return on Equity (ROE) | -163.23 |
| Return on Assets (ROA) | -122.36 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Alzamend Neuro Inc's stock has declined approximately -44.68085% over the past 52 weeks. The 50-day moving average sits at 1.59, while the 200-day moving average is 1.52.
| Beta (5Y) | N/A |
| 52-Week Price Change | -44.68085% |
| 50-Day Moving Average | 1.59 |
| 200-Day Moving Average | 1.52 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -8.98M, while operating income came in at -9.09M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -9.09M |
| Pretax Income | -9.10M |
| Net Income | -9.10M |
| EBITDA | -8.98M |
| EBIT | -9.09M |
| Earnings Per Share (EPS) | -2.34 |
Balance Sheet
Total book value stands at 5.80M, with working capital of 5.52M providing operational flexibility.
| Cash & Cash Equivalents | 7.59M |
| Total Debt | N/A |
| Net Debt | -7.59M |
| Equity (Book Value) | 5.80M |
| Book Value Per Share | 1.20 |
| Working Capital | 5.52M |
Cash Flow
Alzamend Neuro Inc produced -6.84M in operating cash flow over the past twelve months.
| Operating Cash Flow | -6.84M |
| Capital Expenditures | N/A |
| Free Cash Flow | -6.84M |
| FCF Per Share | -1.76 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -139.43 |
| FCF Yield | -134.36 |
Stock Splits
Alzamend Neuro Inc's most recent stock split took place on May 12, 2025 with a 9:1 split ratio.
| Last Split Date | 5/12/2025 |
| Split Ratio | 9:1 |
Scores
Alzamend Neuro Inc posts an Altman Z-Score of -12.88, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -12.88 |